153 related articles for article (PubMed ID: 32911136)
1. Serum high-mobility group box 1 as a predictive marker for cytotoxic chemotherapy-induced lung injury in patients with lung cancer and interstitial lung disease.
Nakao S; Yamaguchi K; Iwamoto H; Sakamoto S; Horimasu Y; Masuda T; Miyamoto S; Nakashima T; Ohshimo S; Fujitaka K; Hamada H; Hattori N
Respir Med; 2020 Oct; 172():106131. PubMed ID: 32911136
[TBL] [Abstract][Full Text] [Related]
2. Predictive role of circulatory HMGB1 in postoperative acute exacerbation of interstitial lung disease in lung cancer patients.
Yamaguchi K; Nakao S; Iwamoto H; Kagimoto A; Handa Y; Sakamoto S; Horimasu Y; Masuda T; Mimae T; Miyamoto S; Nakashima T; Tsutani Y; Fujitaka K; Miyata Y; Hamada H; Okada M; Hattori N
Sci Rep; 2021 May; 11(1):10105. PubMed ID: 33980944
[TBL] [Abstract][Full Text] [Related]
3. Association between glucose intolerance and chemotherapy-induced lung injury in patients with lung cancer and interstitial lung disease.
Otani T; Yamaguchi K; Nakao S; Sakamoto S; Horimasu Y; Masuda T; Miyamoto S; Nakashima T; Iwamoto H; Fujitaka K; Hamada H; Hattori N
Cancer Chemother Pharmacol; 2021 Nov; 88(5):857-865. PubMed ID: 34350479
[TBL] [Abstract][Full Text] [Related]
4. Surfactant protein-D predicts prognosis of interstitial lung disease induced by anticancer agents in advanced lung cancer: a case control study.
Nakamura K; Kato M; Shukuya T; Mori K; Sekimoto Y; Ihara H; Kanemaru R; Ko R; Shibayama R; Tajima K; Koyama R; Shimada N; Nagashima O; Takahashi F; Sasaki S; Takahashi K
BMC Cancer; 2017 May; 17(1):302. PubMed ID: 28464801
[TBL] [Abstract][Full Text] [Related]
5. Low forced vital capacity predicts cytotoxic chemotherapy-associated acute exacerbation of interstitial lung disease in patients with lung cancer.
Enomoto Y; Inui N; Kato T; Baba T; Karayama M; Nakamura Y; Ogura T; Suda T
Lung Cancer; 2016 Jun; 96():63-7. PubMed ID: 27133752
[TBL] [Abstract][Full Text] [Related]
6. The soluble receptor for advanced glycation end products is potentially predictive of pulmonary arterial hypertension in systemic sclerosis.
Atzeni IM; Al-Adwi Y; Doornbos-van der Meer B; Roozendaal C; Stel A; van Goor H; Gan CT; Dickinson M; Timens W; Smit AJ; Westra J; Mulder DJ
Front Immunol; 2023; 14():1189257. PubMed ID: 37409127
[TBL] [Abstract][Full Text] [Related]
7. Role of Soluble Receptor for Advanced Glycation End Products in Postoperative Fibrotic Lung Injury.
Nakao S; Yamaguchi K; Iwamoto H; Kagimoto A; Mimae T; Tsutani Y; Miyata Y; Hamada H; Okada M; Hattori N
Ann Thorac Surg; 2022 May; 113(5):1617-1623. PubMed ID: 34139190
[TBL] [Abstract][Full Text] [Related]
8. Distinctive impact of pre-existing interstitial lung disease on the risk of chemotherapy-related lung injury in patients with lung cancer.
Ozawa Y; Akahori D; Koda K; Abe T; Hasegawa H; Matsui T; Tanahashi M; Niwa H; Yamada K; Yokomura K; Suda T
Cancer Chemother Pharmacol; 2016 May; 77(5):1031-8. PubMed ID: 27048413
[TBL] [Abstract][Full Text] [Related]
9. HMGB1 May Be a Biomarker for Predicting the Outcome in Patients with Polymyositis /Dermatomyositis with Interstitial Lung Disease.
Shu X; Peng Q; Lu X; Wang G
PLoS One; 2016; 11(8):e0161436. PubMed ID: 27537498
[TBL] [Abstract][Full Text] [Related]
10. Association of the RAGE/RAGE-ligand axis with interstitial lung disease and its acute exacerbation.
Yamaguchi K; Iwamoto H; Sakamoto S; Horimasu Y; Masuda T; Miyamoto S; Nakashima T; Fujitaka K; Hamada H; Hattori N
Respir Investig; 2022 Jul; 60(4):531-542. PubMed ID: 35504814
[TBL] [Abstract][Full Text] [Related]
11. The extent of ground-glass attenuation is a risk factor of chemotherapy-related exacerbation of interstitial lung disease in patients with non-small cell lung cancer.
Masuda T; Hirano C; Horimasu Y; Nakashima T; Miyamoto S; Iwamoto H; Ohshimo S; Fujitaka K; Hamada H; Hattori N
Cancer Chemother Pharmacol; 2018 Jan; 81(1):131-139. PubMed ID: 29143072
[TBL] [Abstract][Full Text] [Related]
12. Independent review of interstitial lung disease associated with death in TRIBUTE (paclitaxel and carboplatin with or without concurrent erlotinib) in advanced non-small cell lung cancer.
Yoneda KY; Shelton DK; Beckett LA; Gandara DR
J Thorac Oncol; 2007 Jun; 2(6):537-43. PubMed ID: 17545850
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of S-1 in combination with carboplatin in non-small cell lung cancer patients with interstitial lung disease: a pilot study.
Sekine A; Satoh H; Baba T; Ikeda S; Okuda R; Shinohara T; Komatsu S; Hagiwara E; Iwasawa T; Ogura T; Kato T
Cancer Chemother Pharmacol; 2016 Jun; 77(6):1245-52. PubMed ID: 27130459
[TBL] [Abstract][Full Text] [Related]
14. Outcome in advanced non-small cell lung cancer patients with successful rechallenge after recovery from epidermal growth factor receptor tyrosine kinase inhibitor-induced interstitial lung disease.
Kashiwabara K; Semba H; Fujii S; Tsumura S
Cancer Chemother Pharmacol; 2017 Apr; 79(4):705-710. PubMed ID: 28258422
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the safety and efficacy of combination chemotherapy with vinorelbine and platinum agents for patients with non-small cell lung cancer with interstitial lung disease.
Okuda K; Hirose T; Oki Y; Murata Y; Kusumoto S; Sugiyama T; Ishida H; Shirai T; Nakashima M; Yamaoka T; Ohnishi T; Ohmori T
Anticancer Res; 2012 Dec; 32(12):5475-80. PubMed ID: 23225454
[TBL] [Abstract][Full Text] [Related]
16. Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib.
Ando M; Okamoto I; Yamamoto N; Takeda K; Tamura K; Seto T; Ariyoshi Y; Fukuoka M
J Clin Oncol; 2006 Jun; 24(16):2549-56. PubMed ID: 16735708
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of preexisting interstitial lung disease in Japanese patients with small-cell lung cancer.
Togashi Y; Masago K; Handa T; Tanizawa K; Okuda C; Sakamori Y; Nagai H; Kim YH; Mishima M
Clin Lung Cancer; 2012 Jul; 13(4):304-11. PubMed ID: 22169479
[TBL] [Abstract][Full Text] [Related]
18. Nivolumab-induced interstitial lung disease analysis of two phase II studies patients with recurrent or advanced non-small-cell lung cancer.
Kato T; Masuda N; Nakanishi Y; Takahashi M; Hida T; Sakai H; Atagi S; Fujita S; Tanaka H; Takeda K; Satouchi M; Namba Y; Tamura T
Lung Cancer; 2017 Feb; 104():111-118. PubMed ID: 28212992
[TBL] [Abstract][Full Text] [Related]
19. Increased serum calpain activity is associated with HMGB1 levels in systemic sclerosis.
Zheng JN; Li Y; Yan YM; Yu Y; Shao WQ; Wang Q
Arthritis Res Ther; 2020 May; 22(1):110. PubMed ID: 32393322
[TBL] [Abstract][Full Text] [Related]
20. Predictive value of
Akaike K; Saruwatari K; Oda S; Shiraishi S; Takahashi H; Hamada S; Iyama S; Horio Y; Tomita Y; Saeki S; Okamoto S; Ichiyasu H; Fujii K; Sakagami T
Int J Clin Oncol; 2020 Apr; 25(4):681-690. PubMed ID: 31781994
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
